InvestorsHub Logo
Followers 68
Posts 5584
Boards Moderated 0
Alias Born 01/13/2012

Re: Simpsonly post# 123229

Sunday, 02/18/2018 11:14:07 AM

Sunday, February 18, 2018 11:14:07 AM

Post# of 329222
Pssssst - here’s the real BIEL SLEEPER I forgot to include below, and the one I have believed for years just may become a close second to ActiPatch. If we all put our memories into action, how many women in our lives, family, friends, those we have known at work, have suffered every month of their lives from menstrual cramping and pain? Grimacing, day’s off, limited family activities, lower productivity and just miserable. BIEL has Allay and I understand it works every bit as well as ActiPatch does on foot, knee, back and general musculoskeletal pain, fibromyalgia and arthritis.

Do a little DD on number of women in the world suffer mild, medium and severe menstrual pain - and those stats are NOT included in the chronic pain category, which is pain lasting more than 3 months - or acute pain, lasting less than 3 months, I believe menstrual pain is in its own category. You will be amazed, tens of millions of women - at least one Allay per year....you know what will happen when that gem hits the word-of-mouth circuit, no drugs, no side-effects.....you know when

Previous post
“Hell, I can issue a competent shareholder update right now that will pass muster anywhere:
BIEL
Primary Product — ActiPatch
USPTO Patents - check
Up to date - check
FDA - partially OTC cleared foot and knee - check
FDA - working with company on back clearance - check
Trial supporting back clearance - finished - check
FDA asked for back data pre-submission meet - check
FDA relationship quality - fine
Signed deals with large U.S. distributors - check, do DD
Ongoing discussions with large U.S. retailers - check, do DD
ActiPatch OTC cleared 50+ countries - check
UK NHS Tariff approved for reimbursement - check
NHS support - trial data, efficacy, safety, price
NHS motives - public safety, efficacy, savings £100’s millions annually
Launch - Publicly announced April 1, 2018 Post-launch ramp-up, 90 days
NHS coverage - 100% insured patients with Rx
Estimated price on NHS Rx launch - $ .009 to $ .02
Estimated price on FDA OTC Back clearance - $ .04 to $ .06
Estimated price on FDA OTC General clearance - $ .075 to $ .09
Estimated price on U.S. retail (CVS, Walgreens) launch - $ .11 to $ .15

Is most of this factual? You bet
Is some of it speculative? You bet
p.s. ActiPatch is the only miniaturized, USPTO patented, drug-free, side-effect free, safe and efficacious (FDA says so), partially FDA OTC cleared, pain management device in the world and it works well. Fact”